Goal of this study

To treat Alzheimer’s disease.


Alzheimer’s disease is a brain disease that gradually destroys memory and thinking skills. This study will investigate the safety and tolerability of a drug named ‘IONIS-MAPTRx’ in patients with mild Alzheimer’s disease. The study will also examine how the drug behaves in the body. IONIS-MAPTRx will be given to the patient intrathecally which means through injection in the cerebrospinal fluid. Cerebrospinal fluid is the liquid in which the brain and spinal cord bathe. IONIS-MAPTRx will be administered once every 4 weeks for a period of 13 weeks.

Who can participate in this study?

Patients who have been diagnosed with mild Alzheimer’s disease and who are between the ages of 50 and 74 may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT03186989

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.